Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

1.0K
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
1.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.8K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.8K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

624
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
624
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

615
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
615
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

689
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Removal notice to Seasonal patterns in diagnosis of chronic coronary syndrome by Ct-angiography -a retrospective single-center experience with 10.022 patients [J Cardiovasc Comp Tomogr 20 (2026) S18].

Journal of cardiovascular computed tomography·2026
Same author

REMOVED: Seasonal Patterns In Diagnosis Of Chronic Coronary Syndrome By Ct-angiography -a Retrospective Single-center Experience With 10.022 Patients.

Journal of cardiovascular computed tomography·2026
Same author

Probing Instantaneous Single-Molecule Chirality in the Planar Ground State of Formic Acid.

Physical review letters·2026
Same author

Optimising access: safety and efficacy of venous closure devices in cryoballoon pulmonary vein isolation.

Frontiers in cardiovascular medicine·2025
Same author

Selective Bond Breaking in CO_{2}^{2+} Induced by Photoelectron Recoil.

Physical review letters·2025
Same author

Electron Diffraction Imaging of Carbon Monoxide via K-Shell Ionization by Compton Scattering of 20 keV Photons.

Physical review letters·2025
Same journal

Mechanistic factors of cardiovascular diseases.

Minerva cardioangiologica·2020
Same journal

Robotic-assisted coronary artery bypass grafting: current knowledge and future perspectives.

Minerva cardioangiologica·2020
Same journal

Features of degenerative mitral valve prolapse in the North East of China: repair characteristics, and short-term follow-up results.

Minerva cardioangiologica·2020
Same journal

Myocardial revascularization in chronic coronary syndromes: does viability matter?

Minerva cardioangiologica·2020
Same journal

Extracorporeal membrane oxygenation for COVID-19: effective weapon or futile effort?

Minerva cardioangiologica·2020
Same journal

Heart and endurance sports: excesses are often unhealthy.

Minerva cardioangiologica·2020
See all related articles

Related Experiment Video

Updated: Apr 29, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K

Treating resistant hypertension with new devices.

H Wienemann1, F Meincke, L Kaiser

  • 1Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany - docbergmann@mac.com.

Minerva Cardioangiologica
|May 17, 2014
PubMed
Summary
This summary is machine-generated.

Resistant hypertension management is challenging. Renal denervation (RDN) offers a new treatment option, with newer devices aiming for improved efficacy and safety in lowering blood pressure.

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

841
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

2.5K

Related Experiment Videos

Last Updated: Apr 29, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

841
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

2.5K

Area of Science:

  • Cardiology
  • Nephrology
  • Interventional Cardiology

Background:

  • Arterial hypertension is a prevalent chronic disease and a major risk factor for cardiovascular and renal complications.
  • Resistant hypertension, defined by high blood pressure despite multiple medications, poses a significant clinical challenge.
  • Renal denervation (RDN) has emerged as an interventional therapy targeting renal sympathetic nerves to reduce blood pressure.

Purpose of the Study:

  • To provide an overview of currently available devices for renal denervation.
  • To discuss advancements in RDN technology focusing on improved efficacy and reduced complications.

Main Methods:

  • Review of existing clinical trial data on renal denervation devices.
  • Analysis of safety and efficacy outcomes from first-generation and newer RDN technologies.
  • Exploration of novel strategies like irrigated catheters and ultrasound devices.

Main Results:

  • First-generation RDN devices demonstrated safety, with success rates around 70% in some trials.
  • The Simplicity HTN-3 trial showed mixed results, potentially due to patient population and a significant sham group effect.
  • Newer RDN devices utilizing irrigated or ultrasound technology aim for more efficient sympathetic nerve destruction and higher responder rates.

Conclusions:

  • Renal denervation is a promising therapeutic option for resistant hypertension.
  • Advancements in RDN device technology, such as irrigated and ultrasound catheters, may enhance treatment effectiveness and patient outcomes.
  • Further research is needed to optimize RDN strategies and identify patient subgroups most likely to benefit.